3 active not recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis rapcabtagene autoleucel (YTB323) - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2025-02-24 | 2026-09-02 |
| A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) Obexelimab, Placebo - Relapsing Multiple Sclerosis | Phase 2 | Active not recruiting | Zenas BioPharma (USA), LLC | 93 | 2024-08-26 | 2025-11-17 |
| A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) Fenebrutinib, Placebo - Relapsing Multiple Sclerosis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 109 | 2022-03-01 | 2026-09-25 |
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2)
fenebrutinib (1)
Hoffmann-La Roche (1) · Novartis Pharmaceuticals (1) · Zenas BioPharma (USA), LLC (1)
Croatia (2) · Czechia (2) · Italy (2) · Spain (2) · United States (2) · Australia (1) · Austria (1) · Belgium (1) · Bosnia and Herzegovina (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Poland (1)